NervGen Pharma Grants Stock Options
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 627,200 incentive stock options. The options were distributed to company employees, with 505,200 options allocated to Officers. These options are exercisable at $2.97 per share with a 10-year duration and vest equally every six months over a two-year period. The grants comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una società biotech in fase clinica specializzata in terapie neurorestorative, ha annunciato l'assegnazione di 627.200 opzioni su azioni incentivate. Le opzioni sono state distribuite ai dipendenti dell'azienda, con 505.200 opzioni assegnate agli ufficiali. Queste opzioni sono esercitabili a $2,97 per azione con una durata di 10 anni e maturano equamente ogni sei mesi per un periodo di due anni. Le assegnazioni sono conformi alle politiche della TSX Venture Exchange e al piano di opzioni su azioni della società.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una empresa biotecnológica en etapa clínica centrada en terapias neurorestaurativas, ha anunciado la concesión de 627,200 opciones de acciones de incentivo. Las opciones se distribuyeron a los empleados de la empresa, con 505,200 opciones asignadas a los directivos. Estas opciones son ejercitables a $2.97 por acción con una duración de 10 años y se consolidan equitativamente cada seis meses durante un período de dos años. Las concesiones cumplen con las políticas de la TSX Venture Exchange y el plan de opciones sobre acciones de la empresa.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)는 임상 단계의 생명공학 회사로 신경 회복 치료에 집중하고 있으며, 627,200개의 인센티브 스톡 옵션을 부여했다고 발표했습니다. 이 옵션은 회사 직원에게 배포되었으며, 505,200개의 옵션이 임원에게 배정되었습니다. 이 옵션은 주당 $2.97에 행사 가능하며, 10년의 기간을 가지고 있으며, 2년 동안 매 6개월마다 균등하게 취득됩니다. 이 부여는 TSX 벤처 거래소의 정책 및 회사의 주식 옵션 계획에 부합합니다.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), une entreprise biopharmaceutique en phase clinique axée sur les thérapies neurorestauratives, a annoncé l'octroi de 627 200 options d'achat d'actions incitatives. Les options ont été distribuées aux employés de l'entreprise, avec 505 200 options attribuées aux dirigeants. Ces options sont exerçables à 2,97 $ par action pour une durée de 10 ans et se concrétisent de manière égale tous les six mois sur une période de deux ans. Les attributions sont conformes aux politiques de la Bourse de croissance TSX et au plan d'options sur actions de l'entreprise.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf neurorestaurative Therapien konzentriert, hat die Gewährung von 627.200 Anreiz-Aktienoptionen bekannt gegeben. Die Optionen wurden an die Mitarbeiter des Unternehmens verteilt, wobei 505.200 Optionen den Führungskräften zugewiesen wurden. Diese Optionen sind zu einem Preis von $2,97 pro Aktie ausübbar und haben eine Laufzeit von 10 Jahren, wobei sie über einen Zeitraum von zwei Jahren alle sechs Monate gleichmäßig fällig werden. Die Gewährungen entsprechen den Richtlinien der TSX Venture Exchange und dem Aktienoptionsplan des Unternehmens.
- None.
- Potential dilution of 627,200 shares (505,200 to Officers) at $2.97 per share
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company's employees, including 505,200 to the company's Officers, exercisable at a price of
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
Contacts
Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241357
FAQ
How many stock options did NervGen Pharma (NGENF) grant in February 2025?
What is the exercise price for NGENF's February 2025 stock options?
What is the vesting schedule for NervGen Pharma's (NGENF) 2025 stock options?
What is the expiration period for NGENF's February 2025 stock options?
